Cascade of care of people diagnosed with HIV in New Zealand between 2006 and 2017.
HIV
antiretroviral therapy
cascade
viral load
Journal
HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
12
07
2020
revised:
24
08
2020
accepted:
17
09
2020
pubmed:
28
10
2020
medline:
15
3
2022
entrez:
27
10
2020
Statut:
ppublish
Résumé
We estimated the proportion of people reported with HIV in New Zealand between 2006 and 2017, and alive in 2017-2019, who were on antiretroviral therapy (ART) and had a suppressed viral load (VL), and explored their associated characteristics. Data were anonymously linked to information on ART and VL within the data collection period (January 2017 to August 2019) using the National Health Index (NHI), Ministry of Health and laboratory datasets, as well as information from clinical specialists. Logistic regression was used to test for associations. Sensitivity analyses were undertaken to estimate the range for the key proportions. Overall, 2355 people were reported with HIV, of whom 116 (5%) had died, 337 (14%) were overseas, and 1701 (72%) were alive in New Zealand; for the remaining 201 (9%) the outcome was unknown. Clinical data were available for 1490 people (87.6%): 1408 (94.5%) were on ART, 11 (< 1%) were not on ART, and for 71 (4.8%) this was unknown. Of those on ART, 1156 (82.1%) had a suppressed VL (< 200 copies/mL), 34 (2.4%) were unsuppressed, and for 218 (15.5%) this was unknown. The estimate of the proportion on ART ranged from 99% to 78%, and those with a suppressed VL ranged from 98% to 78%. Among people with HIV in New Zealand who are under care, a high proportion were on ART and had suppressed VL. Increasing collection of NHIs and better linkage with laboratory information will reduce the number with unknown information and provide more complete VL results in the future.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
122-130Informations de copyright
© 2020 British HIV Association.
Références
Rodger AJ, Lodwick R, Schechter M et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 2013; 27 (6): 973-979.
Anglemyer A, Rutherford GW, Easterbrook PJ et al. Early initiation of antiretroviral therapy in HIV-infected adults and adolescents: a systematic review. AIDS 2014; 28: S105-S118.
Cohen MS, Chen YQ, McCauley M et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med 2016; 375 (9): 830-839.
Rodger AJ, Cambiano V, Bruun T et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA 2016; 316 (2): 171-181.
Rodger AJ, Cambiano V, Bruun T et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet 2019;393 10189:2428-2433.https://doi.org/10.1016/S0140-6736(19)30418-0.
Anglemyer A, Rutherford GW, Horvath T, Baggaley RC, Egger M, Siegfried N. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev 2013; 4 (4): CD009153.
UNAIDS. Undetectable = Untransmittable. Available at https://www.unaids.org/sites/default/files/media_asset/undetectable-untransmittable_en.pdf (Accessed 18 November 2018).
Brown AE, Gill ON, Delpech VC. HIV treatment as prevention among men who have sex with men in the UK: is transmission controlled by universal access to HIV treatment and care? HIV Med 2013; 14 (9): 563-570.
Wilson DP. HIV treatment as prevention: natural experiments highlight limits of antiretroviral treatment as HIV prevention. PLoS Med 2012; 9 (7): e1001231. https://doi.org/10.1371/journal.pmed.1001231.
Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Inf Dis 2011; 52 (6): 793-800.
UNAIDS. 90-90-90: Treatment for all. Available at http://www.unaids.org/en/resources/909090 (Accessed 23 May 2017).
Medland NA, McMahon JH, Chow EP, Elliot JH, Hoy JF, Fairley CK. The HIV care cascade: a systematic review of data sources, methodology and comparability. J Int AIDS Soc 2015; 18: 20634. https://doi.org/10.7448/IAS.18.1.20634.
Granich R, Gupta S, Hall I, Aberle-Grasse J, Hader S, Mermin J. Status and methodology of publicly available national HIV care continua and 90-90-90 targets: a systematic review. PLoS Med 2017; 14 (4): e1002253. Doi: 10.1371/journal.pmed.1002253.
Gisslén M, Svedhem V, Lindborg L et al. Sweden, the first country to achieve the Joint United Nations Programme on HIV/AIDS (UNAIDS)/World Health Organization (WHO) 90-90-90 continuum of HIV care targets. HIV Med 2017; 18 (4): 305-307.
O’Halloran C, Sun S, Nash S et al. HIV in the United Kingdom: Towards Zero 2030. 2019 report. London, Public Health England. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/858559/HIV_in_the_UK_2019_towards_zero_HIV_transmissions_by_2030.pdf (Accessed 15 October 2020).
Kirby Institute. HIV in Australia: Annual surveillance short report 2018. Sydney, Australia, Kirby Institute, UNSW, 2018. https://kirby.unsw.edu.au/sites/default/files/kirby/report/supplHIV2018_content_20180920r.pdf (Accessed 15 October 2020).
Mills G, Yardley A-M, Thomas M et al. New Zealand's HIV infected population under active follow-up during 2000. NZ Med J 2002; 115 (1152): 173-176.
Raymond N, Bargh K, Aung K, Rice J. Cascade of care for people living with HIV infection in the Wellington region. NZ Med J 2016; 129 (1432): 41.
Ministry of Health. National Health Index entitlements. Available at https://www.health.govt.nz/new-zealand-health-system/claims-provider-payments-and-entitlements/national-health-index-entitlements. (Accessed 16 August 2020).
World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach. Geneva, Switzerland, 2016.
Dickson N, Lee B, Foster T, Saxton PJW. The first 30 years of HIV in New Zealand: Review of the epidemiology. NZ Med J 2015; 128 (1426):31-48.
Statistics New Zealand. Available at https://www.stats.govt.nz/topics/ethnicity (Accessed 6 July 2020).
StataCorp. Stata statistical software: Release 12.1. College Station, Texas, USA 2013.
Saxton PJ, Dickson NP, Griffiths R, Hughes AJ, Rowden J. Actual and undiagnosed HIV prevalence in a community sample of men who have sex with men in Auckland, New Zealand. BMC Pub Health 2012; 12 (1): 92.
Porter K, Gourlay A, Attawell K et al. Substantial heterogeneity in progress toward reaching the 90-90-90 hiv target in the WHO European Region. J AIDS (1999) 2018; 79 (1): 28-37.